Lawmakers are making another push to crack down on pharmacy benefit managers, an industry that’s been thrust into the spotlight in the debate over high drug prices in the US.
PBMs have shifted their business models amid the growing scrutiny, relying less on revenue from drugmaker rebates and instead finding new profit sources. The largest three PBMs —
Federal bills to require PBMs to pass ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.